Evidence map›Paper›PMID 42959553›Full record

ReviewExploratory research in clinical and social pharmacy2026

Medication and health-related outcomes by prescription lengths: A systematic review.

Su Myat Thin, Parnnaphat Luksameesate, Chanthawat Patikorn, Suthira Taychakhoonavudh

Abstract readReview
In one paragraph

Review in Exploratory research in clinical and social pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Su Myat ThinDepartment of Social and Administrative Pharmacy, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.
Parnnaphat LuksameesateDepartment of Social and Administrative Pharmacy, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.
Chanthawat PatikornDepartment of Social and Administrative Pharmacy, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.
Suthira TaychakhoonavudhDepartment of Social and Administrative Pharmacy, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Prescription length policies (such as 30, 60, or 90 days) influence medication adherence, healthcare access, costs, and patient safety. However, their overall impact remains unclear because of heterogeneous evidence. Objectives: This systematic review evaluated the effects of prescription length on clinical, economic, and healthcare system outcomes and identified methodological considerations for future research and policy. Methods: PubMed, Scopus, and ScienceDirect were searched for studies published from 2000 to July 1, 2026. Studies comparing different prescription lengths were included, while those unavailable in full text were excluded. Methodological quality was assessed using design-specific critical appraisal tools. Due to substantial heterogeneity in study designs, populations, prescription durations, and outcome measures, findings were synthesized narratively. Results: Twenty-three studies were included. Longer prescription durations were generally associated with improved medication adherence and increased medication waste. Evidence for economic, clinical and healthcare utilization outcomes was more limited and heterogeneous. Among studies of chronic disease management, longer prescription durations were generally associated with lower out-of-pocket costs, transportation cost and patient time cost, and reduced healthcare encounters, although findings for total economic outcomes varied according to the analytical perspective adopted. For acute conditions with opioid use, shorter prescription durations were associated with reduced adverse outcomes, including overdose risk and persistent opioid use. Methodological heterogeneity in study design, outcome definitions, and analytical perspectives contributed to differences in findings across studies. Conclusion: Longer prescription lengths were consistently associated with improved medication adherence but also increased medication waste. Evidence for clinical, economic, and healthcare system outcomes remains limited and heterogeneous and should be interpreted according to medication type and clinical context. Thus, a single prescription duration is unlikely to be appropriate across all settings. Healthcare providers and policymakers should consider medication type, patient needs, treatment stability, and healthcare system context when determining prescription duration. Further well-designed studies using transparent and comparable outcome definitions are needed to strengthen the evidence base for prescription-length decision-making.

Indexed as

CostsMedication adherenceMedication wastePrescription length

Identifiers

PMID42959553
PMCPMC13717161

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.